

Calcitonin receptor expression in medullary thyroid carcinoma

Virginia Cappagli^{1,2,*}, Catarina Soares Potes^{3,4,5,*}, Luciana Bueno Ferreira^{1,3,6}, Catarina Tavares^{1,3,6}, Catarina Eloy^{1,3}, Rossella Elisei², Manuel Sobrinho-Simões^{1,3,7,8}, Peter J. Wookey⁹ and Paula Soares^{1,3,6,8}

¹ Cancer Signaling and Metabolism Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal

² Department of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy

³ Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal

⁴ Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal

⁵ Department of Biomedicine – Experimental Biology Unit, Faculty of Medicine, University of Porto, Porto, Portugal

⁶ Medical Faculty, University of Porto, Porto, Portugal

⁷ Department of Pathology, Hospital de S. João, Porto, Portugal

⁸ Department of Pathology, Medical Faculty, University of Porto, Porto, Portugal

⁹ Department of Medicine at Austin Health, University of Melbourne, Heidelberg, VIC, Australia

* These authors contributed equally to this work.

ABSTRACT

Background: Calcitonin expression is a well-established marker for medullary thyroid carcinoma (MTC); yet the role of calcitonin receptor (CTR), its seven-transmembrane G-protein coupled receptor, remains to be established in C-cells derived thyroid tumors. The aim of this work was to investigate CTR expression in MTC and to correlate such expression with clinicopathological features in order to evaluate its possible role as a prognostic indicator of disease aggressiveness and outcome.

Methods: Calcitonin receptor expression was analyzed in a series of 75 MTCs by immunohistochemistry, and by qPCR mRNA quantification in specimens from four patients. Statistical tests were used to evaluate the correlation between CTR expression and the clinicopathological and molecular characteristics of patients and tumors.

Results: Calcitonin receptor expression was detected in 62 out of 75 samples (82.7%), whereas 13 of the 75 samples (17.3%) were completely negative. CTR expression was significantly associated with expression of cytoplasmic phosphatase and tensin homologue deleted on chromosome 10 and osteopontin, as well as with wild type *RET/RAS* genes and absence of tumor stroma, suggesting that CTR expression do not associate with clinicopathological signs of worse prognosis.

Discussion: Calcitonin receptor expression appears to be associated in MTC with more differentiated status of the neoplastic cells.

Subjects Molecular Biology, Diabetes and Endocrinology, Oncology

Keywords Calcitonin receptor, Calcitonin, C-cells, Medullary thyroid carcinoma

Submitted 25 January 2017
Accepted 17 August 2017
Published 13 September 2017

Corresponding author
Paula Soares, psoares@ipatimup.pt

Academic editor
Kevin Petrie

Additional Information and
Declarations can be found on
page 12

DOI 10.7717/peerj.3778

© Copyright
2017 Cappagli et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

INTRODUCTION

Medullary thyroid carcinoma (MTC) is a rare tumor representing 5–10% of thyroid cancers (*Elisei et al., 2013*). It is a tumor with neuroendocrine differentiation and arises from the parafollicular C-cells of the thyroid which normally secrete calcitonin (CT). MTC originates as a sporadic (75–80%) malignancy or a manifestation of hereditary syndromes (20–25%), i.e., multiple endocrine neoplasia type 2 (MEN2A or MEN2B)/familial MTC, with an autosomal dominant pattern due to germline mutations of the *RET* gene (*Pacini et al., 2010*). In both forms of MTC (sporadic and familial) the clinic-laboratorial diagnosis is based mainly on the finding of elevated levels of serum CT, in basal and stimulated conditions. Serum CT is a very sensitive and specific method for diagnosing MTC, even though some other pathological/physiological conditions can be associated with increased levels of that hormone (*Elisei et al., 2013*). The clinical behavior of MTC is less favorable compared to follicular cell-derived thyroid tumors: 10 year survival rate is about 50–75% and the most important prognostic factor is tumor stage at diagnosis (*Elisei et al., 2013; Kloos et al., 2009*).

Calcitonin is a polypeptide hormone of 32 amino acids which is involved in the regulation of calcium homeostasis (*Muff et al., 2004; Wimalawansa, 1997*) under conditions of hypercalcaemia (*Turner et al., 2011*). It has been shown the osteoanabolic action of CT (*Keller et al., 2014*). CT has also been implicated in protecting the skeleton from excessive loss of bone during periods of high calcium demand, such as lactation (*Davey & Findlay, 2013*). In experimental models CT secretion was inhibited by high levels of CT suggesting a possible negative feedback mechanism (as for other endocrine system molecules) and autocrine regulation of normal C-cells (*Kakudo et al., 1989; Morimoto et al., 1984; Orme & Pento, 1976*).

Calcitonin binds specific calcitonin receptors (CTRs) that belong to the family B of G-protein coupled receptors (*Chakraborty et al., 1991; Conner et al., 2002; Lin et al., 1991; Poyner et al., 2002*). In mammals, CTR is widely expressed during blastula implant and during fetal (*Jagger, Chambers & Pondel, 2000; Pondel, 2000; Tolcos et al., 2003*) and perinatal (*Tikellis et al., 2003; Wookey, Turner & Furness, 2012b*) development. In adult tissues, CTR is widely expressed, for example in neural networks (*Becskei et al., 2004; Sexton, McKenzie & Mendelsohn, 1988*), in osteoclasts and osteocytes (*Gooi et al., 2010*), renal distal epithelium, B and T-cells (*Body et al., 1990; Cafforio et al., 2009*), testis (*Chausmer, Stuart & Stevens, 1980*), lung (*Fouchereau-Peron et al., 1981*) and several other tissues (reviewed in *Findlay (2006)* and *Wookey et al. (2010)*). CTR is also expressed by specific cell types in wound healing (*Wookey et al., 2010*), in cardiovascular diseases (*Wookey et al., 2008; Wookey, Zulli & Hare, 2009*) and in several types of malignant tissues as breast (*Gillespie et al., 1997*) and prostate cancer (*Thomas et al., 2006*), as well as in cell lines derived from neoplasias of the lung (*Findlay et al., 1980; Findlay, Michelangeli & Robinson, 1989*), breast (*Findlay et al., 1981; Gillespie et al., 1997; Kuestner et al., 1994*), brain (*Wookey et al., 2012a*), bone osteoclasts (*Gorn et al., 1995; Nicholson et al., 1987*), prostate (*Thomas, Muralidharan & Shah, 2007*), and of lymphoid (*Marx et al., 1974*) and myeloid tissues (*Gattei et al., 1992; Silvestris et al., 2008*).

Calcitonin receptor is the only receptor for CT characterized to date, and serves also as the signaling protomer for the heteromeric amylin receptor (CTR/RAMP-1). A unifying physiological role for CTR and its ligands in the previously mentioned situations remains to be advanced.

Calcitonin receptor function is best characterized as coupling to the stimulatory G α subunit to increase adenylate cyclase (cAMP) activity and to activate downstream cAMP sensors PKA and Epac but has also been shown to couple to intracellular calcium mobilization and extracellular regulated kinase phosphorylation. In humans, two different isoforms of CTR, generated by alternative splicing, have been reported. These two forms differ by an insert of 16 amino acids in the first intracellular loop (CTR C1b [I⁺, insert⁺], 483 amino acids while CTR C1a [I⁻, insert⁻] is 467 amino acids in length) (Frendo *et al.*, 1994; Gorn *et al.*, 1992; Kuestner *et al.*, 1994).

Frendo *et al.* demonstrated for the first time in 1994, the expression of the isoform CTR1a in thyroid cell lines (TT cell line derived from MTC) and in two MTC cases (Frendo *et al.*, 1994). In subsequent studies Frendo *et al.* showed that CTR C1a mRNA was present in both normal and tumoral MTC thyroid tissue. No differences were found between sporadic and familial MTC regarding the expression of CTR C1a mRNA (Frendo *et al.*, 1998a, 1998b). Higher expression of CTR C1a mRNA was found in MTC samples compared with normal tissue, and it was also reported that CTR C1a mRNA levels were modified during cell proliferation (Frendo *et al.*, 1998b). The putative function of CTR in malignant tissues and tumor cell lines are still largely unknown and different results have been reported according to the different affected tissue. In breast cancer cell lines, there is evidence of an anti-proliferative effect of CTR activation (Nakamura *et al.*, 2007; Ng *et al.*, 1983), while in prostate cancer the up-regulation of the CT/CTR axis seems to help the switch of prostate cells towards a malignant phenotype (Thomas *et al.*, 2006, Thomas, Muralidharan & Shah, 2007) stimulating proliferation, metastization and angiogenesis.

There are no studies evaluating levels of expression of CTR protein on MTC. Furthermore, no association between CTR mRNA or serum CT levels with the clinical characteristics or the prognosis of the patients with MTC have been reported (Frendo *et al.*, 1998b). Given the lack of data regarding protein expression and the possible role of CTR in MTC, we decided to evaluate the expression of CTR protein in a large series of MTC and to correlate the expression level with molecular and clinicopathological features.

MATERIALS AND METHODS

Human MTC tissue samples

A total of 75 MTC samples diagnosed in two institutions were used in the present study. Formalin-fixed, paraffin-embedded tissue and the corresponding clinical data were retrieved from the files of the Centro Hospitalar S. João (CHSJ)/Medical Faculty of Porto (FMUP)/Ipatimup (55 cases) and the Portuguese Institute of Oncology, Coimbra (IPO-C) (20 cases). The diagnosis of MTC was revised by two pathologists (CE and MSS) and confirmed by calcitonin immunostaining. Clinicopathological and follow-up data were obtained from the surgical pathology reports and patients' records of the

Department of Pathology and Oncology of CHSJ and from IPO database ([Supplementary Table](#)). The series from Ipatimup included consultation cases from which only limited demographic and clinical information was available. *RET* and *RAS* genetic characterization of the series have been previously reported ([Lyra et al., 2014](#)). The study was approved by the Hospital Ethical Committee of the Centro Hospitalar São João/Faculdade de Medicina da Universidade do Porto (CES 284/13) and the National Ethical rules were followed in every procedure.

Immunohistochemistry

Immunohistochemistry (IHC) for human CTR was performed in representative tumor sections of the 75 MTC cases. The mouse monoclonal anti-human CTR antibody (mAb) 31/01-1H10 against a cytoplasmatic epitope within the carboxyl terminal of human CTR (DIPIYICHQELRNEPANN; Welcome Receptor Antibodies Pty Ltd., Melbourne, Australia; also distributed as MCA2191 by BioRad AbD Serotec) was used, which was already characterized in previous studies ([Silvestris et al., 2008](#); [Wookey et al., 2008, 2012a](#); [Wookey, Zulli & Hare, 2009](#)). Deparaffinized and rehydrated sections were subjected to microwave treatment in 10 mM sodium citrate buffer, pH 6.0, for antigen retrieval. After blocking, the sections were incubated overnight at 4 °C in a humidified chamber with the primary antibody anti-CTR (mAb 31/01-1H10 1:4,000). For the detection, a labelled streptavidin–biotin immunoperoxidase detection system was employed (Thermo Scientific/Lab Vision, Fremont, CA, USA), and the immunohistochemical staining was developed with 3,3'-diaminobenzidine substrate. A negative control consisting on the omission of the primary antibody was performed. IHC evaluation was performed independently by two observers (CE and VC). CTR expression was evaluated taking into account the proportion of stained cells (scored as $\leq 5\%$ = 0; 5–25% = 1; 25–50% = 2, 50–75% = 3 and 75–100% = 4) and the staining intensity (scored as absent = 0, faint = 1, moderate = 2 and strong = 3) ([Table 1](#)). CTR expression was semi-quantified using a staining score (from 0 to 12) corresponding to the multiplication of the staining intensity by the proportion of positive stained cells ([Table 2](#)) as previously described by our group ([Ferreira et al., 2016](#); [Lyra et al., 2014](#)). CTR expression was correlated with data previously obtained by our group in this series of tumors with regard to phosphatase and tensin homologue deleted on chromosome 10 (PTEN), phospho-S6 ribosomal protein (pS6) ([Lyra et al., 2014](#)) and osteopontin (OPN) IHC expression ([Ferreira et al., 2016](#)).

Calcitonin staining with a rabbit monoclonal antibody (ref.: RM-9117-S, clone SP17, Neomarkers) was performed for diagnostic purposes and CT immune-expression was semi-quantified, based on the intensity of the staining, in a score from 1 to 4. In the majority of the cases the staining of CT and CTR was done in serial sections. The CT score obtained was correlated with the corresponding CTR expression score in each case (64/75 cases; in 11 cases we do not have access to the calcitonin staining slides).

Table 1 Staining intensity and extension of CTR expression in the 75 MTC cases.

Intensity expression	<i>n</i>	%	Cellular expression (%)	<i>n</i>	%
Absent	11	14.7	<5	13	17.3
Faint	26	34.7	5–25	0	0
Moderate	19	25.3	25–50	7	9.3
Strong	19	25.3	50–75	4	5.3
			75–100	51	68
Total	75	100		75	100

Table 2 Staining score of CTR IHC in the 75 MTC cases.

CTR staining score ^a	<i>n</i>	%
0	13	17.3
2	6	8
3	4	5.3
4	15	20
8	18	24
12	19	25.3
Total	75	100%

Note:

^a Product of the staining intensity by the proportion of positive cells; scores of 1, 5, 6, 7, 9, 10 and 11 were not obtained in any case.

RNA extraction and reverse transcription

Total RNA was extracted from frozen specimens of MTC ($n = 4$), from adjacent normal tissue specimens ($n = 5$) and from two MTC-derived cell lines (TT, purchased from American Type Culture Collection – ATCC; and MZ-CRC-1, provided by Dr. Robert Hofstra, Netherlands) using a Trizol commercial kit (Life Technologies; GIBCO BRL, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA was quantified by spectrophotometry and its quality was checked by analysis of 260/280 nm and 260/230 nm ratios. For cDNA preparation, 1 μ g of total RNA was reverse transcribed using the RevertAid first strand cDNA synthesis kit (Fermentas, Burlington, ON, Canada).

Real time PCR

Reverse transcription products of CTR were amplified by real-time quantitative PCR (#HS.PT.56a.40988589; IDT, Coralville, IA, USA) using the TaqMan[®] PCR Master Mix (Applied Biosystems, Foster City, CA, USA) with TBP gene (TATA-binding protein) as endogenous control (#4326322E-0705006; Applied Biosystems). The ABI PRISM 7500 Fast Sequence Detection System (Applied Biosystems) was used to detect the amplification level and was programmed to an initial step of 2 min at 50 °C, 10 min at 95 °C, followed by 45 cycles of 95 °C for 15 s and 60 °C for 1 min. The relative quantification of target genes was determined using the $\Delta\Delta$ CT method, which was previously validated by Livak's linear regression method (slope = 0.0696) (Sequence Detector User Bulletin 2; Applied Biosystems). Primers used for qPCR are available at the manufacturer's website.

Statistical analysis

Statistical analysis was performed using 22.0 SPSS statistical package (IBM, Armonk, NY, USA). The relationship between the immunohistochemical score of CTR and clinicopathological features was evaluated by independent sample *t*-test or Mann–Whitney test (for comparisons of groups having less than 30 cases). The correlation between the immunoreactivity of the other proteins (PTEN, pS6, OPN and CT) with CTR was assessed using the Pearson correlation test. A $p \leq 0.05$ was considered statistically significant.

RESULTS

CTR protein expression in MTC

Calcitonin receptor expression was mainly localized in the cytoplasm and was detected in 62 out of 75 samples (82.7%), while the remaining 13 samples (17.3%) were negative. In the 62 positive samples, CTR expression was present in more than 50% of the cells in 55 cases (88.7%) (Table 1) and the staining intensity was faint in 34.7%, moderate in 25.3% and strong in 25.3% (Table 1). The distribution of the staining score among the positive cases is present in Table 2. In a few cases, scattered nuclear staining was observed. Examples of representative cases and the negative controls are shown in Fig. 1 (additional staining patterns are shown in Fig. S1).

Correlation of CTR expression with clinicopathological and molecular features of MTC

No significant associations were observed between CTR expression and age of the patients, tumor dimension, lymph node and/or distant metastases tumoral invasion nor extrathyroidal extension (Table 3). Tumors from female patients had significantly higher CTR expression (Table 3).

The characteristics of the tumoral stroma were evaluated separately, accounting for the presence of either an amyloid stroma or a hyaline/desmoplastic stroma *versus* the absence of any kind of stroma. MTC samples without desmoplastic stroma had significantly higher expression of CTR (7.9 vs 5.5, $p = 0.04$) than tumors presenting hyaline/desmoplastic stroma, while there was no correlation with the presence/absence of an amyloid stroma.

Tumors wild-type for *RAS* or *RET* genes had higher CTR expression when compared to mutated cases (7.3 vs 5.2, $p = 0.04$; Table 2). The same trend was observed when these mutations were analyzed separately but the differences did not reach statistical significance ($p = 0.07$, for *RAS*-positive cases versus wild-type for both mutations and $p = 0.09$ for *RET*-positive tumors versus tumors wild-type for both mutations).

There was a strong positive correlation between CT staining and CTR expression, ($p = 0.001$), that is, the cases with higher score for CT staining showed also higher CTR expression (Fig. 2).

The immunohistochemical detection of other cancer related proteins such as PTEN, pS6 and OPN had been previously analyzed in the same series of MTCs (Lyra *et al.*, 2014; Ferreira *et al.*, 2016). In this study we evaluated the relationship between the expression of those markers with CTR expression. Tumors with cytoplasmatic PTEN expression




Figure 1 CTR expression in MTC. (A and B) negative control, a MTC case in which the primary antibody was omitted. (C and D) negative CTR-expression in a case of MTC. (E and F) positive CTR-expression in a case of MTC (score 2: extent 25–50%, intensity 1+). (G and H) positive CTR-expression in a case of MTC (score 12: extent 100%, intensity 3+). The dashed square in (A), (B) and (C) photomicrographs taken at 10× magnification represents the area in (D), (E) and (F) pictures taken using the 60× objective. Bar 100 μm.

Table 3 Clinicopathological and molecular associations with CTR expression.

Clinicopathological (N)	CTR expression (mean ± SD)	<i>p</i> ^c Value
Gender		0.044
Female (29)	(6.8 ± 4.8)	
Male (25)	(4.4 ± 3.50)	
Tumor size (cm)		0.55
<2 (18)	(5.7 ± 4.6)	
≥2 (20)	(4.9 ± 4.5)	
Stroma		0.042
Absent (20)	(7.9 ± 4.2)	
Present (hyaline) (51)	(5.6 ± 4.3)	
Amyloid deposits		0.91
Absent (14)	(5.5 ± 4.2)	
Present (26)	(5.4 ± 4.6)	
Extrathyroidal extension^a		0.42
Absent (7)	9.5	
Present (14)	11.8	
Metastases^a		0.96
Absent (11)	15.1	
Present (18)	14.9	
Invasion (vascular and/or capsular)^a		0.62
Absent (4)	14.6	
Present (21)	12.7	
RET		0.26
Wild type (37)	(6.65 ± 4.54)	
Mutated (38)	(5.53 ± 4.19)	
RAS		0.11
Wild type (66)	(6.38 ± 4.37)	
Mutated (9)	(3.89 ± 3.88)	
RET or RAS mutation		0.046
Wild type (29)	(7.34 ± 4.47)	
Mutated (46) ^b	(5.28 ± 4.16)	

Notes:

^a For these variables the Mann–Whitney non parametric test (group < 30 cases) was used; the CTR protein expression is reported as mean rank.

^b A case presented a *RET* and a *RAS* mutation.

^c The bold entries correspond to statistical significant values.

presented significantly higher CTR expression compared to PTEN cytoplasmic negative cases ($p = 0.038$). There was also a significant association between OPN expression and CTR expression ($p = 0.009$). No correlation was found between CTR and pS6 expression ($p = 0.21$).

CTR mRNA expression in MTC

Calcitonin receptor mRNA levels were analyzed in four cases of MTC and adjacent non-tumoral thyroid tissue from which frozen samples were available, and also in two




Figure 2 CT and CTR staining in serial MTC tissue sections. (A and D) CTR score 0 and CT intensity 1. (B and E) CTR score 4 (extent 75–100%, intensity 1), CT intensity 3. (C and F) CTR score 12 (extent 75–100%, intensity 3), CT intensity 4. Note that higher CTR scores correspond to more intense CT stainings. Photomicrographs were taken at 10× magnification. Bar 100 μ m.

MTC-derived cell lines (TT and MZ-CRC-1). A similar expression of CTR mRNA was observed in adjacent thyroid tissue and MTC (Fig. 1) except in one case in which a much higher expression was observed in the tumor than in the respective adjacent thyroid parenchyma. We must emphasize that the low number of C-cells present in adjacent normal parenchyma limits this analysis. Both MTC-derived cell lines expressed CTR mRNA (Fig. 3); the expression was higher in TT cell line than in MZ-CRC-1 (TT = 0.498658 vs MZ-CRC-1 = 0.1280699).

DISCUSSION

This is the first study in which expression levels of CTR protein were evaluated in a large series of MTC cases. The study of the expression of CTR mRNA and of the function of CT/CTR in MTC is limited to few papers that analyzed a limited number of cases (Frendo *et al.*, 1998a, 1998b, 1994). In the present study the expression of CTR protein was evaluated in 75 MTC cases and this information was used to search for correlations with clinicopathological and molecular features. We observed CTR expression in 82.7% (62/75) of MTC cases.

At variance with the results obtained in other tumor models, in our series high levels of CTR protein expression did not correlate with poor prognosis or aggressive features of MTC. On the contrary, there was a tendency for CTR to be more expressed in smaller tumors, without capsular or vascular invasion and without distant metastases. These findings could suggest that CTR expression might be associated to tumor differentiation. Further studies in large series are necessary to confirm (or not) this tendency.

Frendo *et al.* (1998a, 1994) observed that in MTC and TT cell lines, the shorter isoform of CTR (CTR C1a) was expressed and that CTR mRNA was present both in normal and tumor tissue with higher levels in tumors and without differences among the different clinical forms of MTC (Frendo *et al.*, 1998b). Our hypothesis that higher expression of




Figure 3 CTR mRNA expression in thyroid tissues and in two MTC cell lines.

CTR in MTC may be associated with a more differentiated status of the neoplastic cells is consistent with the demonstration that inhibition of proliferation of the TT cell line correlated with increased expression and secretion of CT (*deBustros et al., 1986*). The expression of CTR mRNA in two MTC derived cell lines open the possibility of further functional studies with siRNA to evaluate in vitro the consequences of CTR gene silencing in the differentiation of MTC cells. The close homology between several molecules: CT/CTR (independent of RAMPs), amylin receptors with CTR/RAMPs 1, 2 or 3 and, CGRP receptors defined by CTR/RAMP 2 (as well as CRLR/RAMP 1) can, however, be a limiting factor in those studies.

We must also consider the possibility of transient epithelial–mesenchymal transition (EMT) as it was recently reported by *Johansson et al. (2015)* in MTC where “differentiation genes” are repressed in locally invasive tumor cells but re-expressed at metastatic sites. In this sense it will be also very interesting to explore the expression of CTR in primary and metastatic MTC lesions, as well as in the invasive front vs tumor bulk, in combination with lineage specific markers (Foxa1/Foxa2) and epithelial–mesenchymal transition markers.

In our hands, CTR expression correlated with CT expression at the protein (IHC) level. Taken together, these data fit with the assumption that a more differentiated MTC status, as evaluated by CT levels, is associated with elevated expression of CTR (*Fig. 2*).

There seems to be an association of OPN expression and a more differentiated MTC status. *Briese et al. (2010)* demonstrated a higher expression of the OPN protein in MTC than in normal thyroid. Our group confirmed this association through the finding that OPN is correlated with features of better prognosis of MTC and with C-cell differentiation (*Ferreira et al., 2016*). OPN is a matricellular glycoprotein involved in biological processes, as biomineralization, bone remodeling and immune responses, and also in pathological processes. In the present study we found a strong positive correlation between CTR expression and OPN expression and this finding reinforces the hypothesis that CTR is probably related with C-cell differentiation.

Phosphatase and tensin homologue deleted on chromosome 10 is a phosphatase enzyme and acts as tumor suppressor with different functions according to its subcellular

localization (Bononi & Pinton, 2015; Chung & Eng, 2005). PTEN is an important down-regulator of Akt/mTOR, a pathway that is involved in MTC tumorigenesis (Tamburrino et al., 2012). In a previous study of our group (Lyra et al., 2014) we proposed that, in MTCs, RAS mutation plays a direct role in the activation of mTOR pathway, while in RAS wild type tumors the mTOR pathway appear to be activated by a mechanism involving a lower expression of cytoplasmatic PTEN. In the present study we observed that higher expression of CTR correlated with higher cytoplasmic PTEN expression in MTC. In accordance with our previous results we found that tumors wild-type for RAS or RET had significantly higher CTR expression when compared to mutated tumors. Further studies are necessary to evaluate the role of CTR in this context.

The role of stroma in the regulation of tumorigenesis is largely acknowledged (Tlsty & Coussens, 2006). The stromal reaction has been described in several tumor types and it has been related with a more invasive and aggressive tumor behavior in most of such models (Rowley, 1998). This holds particularly true in MTC in which several studies (Koperek et al., 2008; Scheuba et al., 2006) have associated the presence of a “hyaline/desmoplastic” stroma with more aggressive features (tumor size, tumor stage, more invasive tumors and the presence of lymph node metastases). In the present series, we observed a significantly higher expression of CTR in cases without or with discrete tumor stroma. Putting these results together we think that our results reinforce the idea that CTR may be a marker of better differentiation, less invasive and less aggressive tumors.

The CT/CTR axis in tumors is not well understood and the studies on record report dissimilar data according to different tumor models. In prostate, several studies (Chigurupati et al., 2005; Shah et al., 2009; Thakkar et al., 2013; Thomas et al., 2006, Thomas, Muralidharan & Shah, 2007), using primary tumor samples and cell lines, suggested a tumorigenic role of CTR. In particular, it was demonstrated that there was a different spatial expression between normal and tumor tissue with a higher expression in the tumors and that, while in the early stage of prostate cancer the tumor cells expressed either CT or CTR, in the advanced cases there was a co-expression of both and such co-expression associated with a metastatic phenotype (Thakkar et al., 2013). Furthermore, a higher expression of CT/CTR correlated with a higher tumor grade and a worsen prognosis (Thakkar et al., 2013). In prostate cancer, the most important pathway upregulated through CTR activation is cAMP, leading to a higher invasiveness due to the degradation of extracellular matrix by PKA and urokinase-plasminogen A system (Thomas et al., 2006). In contrast to this, in breast cancer, CT/CTR seems to play a protective role as Ng et al. (1983) showed that CT was able to inhibit the growth of a breast cancer cell line. In subsequent studies, other groups (Gillespie et al., 1997; Wang et al., 2004) demonstrated that CTR, mostly the isoform 2, was expressed in tumor samples and cell lines and that a decreased CTR expression was observed in advanced tumors with lymph node metastases and lymphatic invasion. Finally, CTR was shown to be involved in the control of breast cancer invasion by downregulating the activity of urokinase-plasminogen A and inhibiting cells invasiveness in a concentration-dependent manner (Han et al., 2006). Our results regarding the CTR expression in MTC and its correlation

with patients' prognosis are more alike the breast cancer model, namely regarding the tendency for CTR to be more expressed in smaller tumors, without invasion and metastases. Unfortunately, data concerning the final outcome of the patients was only available in 20 out of the 75 cases and this represents a major limitation. From these 20 cases 13 were CTR-positive (65%) and 7 were CTR-negative (35%). Considering the outcome of the patients, seven out of 20 patients are free of disease being five CTR-positive (71%) and two CTR-negative (29%) whereas in the group of the five patients that died due to the disease, two (40%) were CTR-positive and three (60%) were CTR-negative. This tendency to lower CTR expression in patients with guarded prognosis needs to be verified in a larger MTC series.

CONCLUSION

In summary, the present study confirms that CTR is expressed in most MTCs and our data seems to suggest that CTR expression in MTCs is associated with a more differentiated status and clinical and molecular features of good prognosis. Further studies are needed to clarify the function of CTR in normal and tumoral C-cells.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This study was supported by ERASMUS+ grant to VC and by Fundação para a Ciência e Tecnologia through the post-doctoral grant SFRH/BPD/87537/2012 to CSP and the doctoral grant SFRH/BD/87887/2012 for CT. This study was supported by a CNPq PhD Scholarship (“National Counsel of Technological and Scientific Development”, Brazil), Science Without Borders, Process n# 237322/2012-9 for LBF. Further funding from the project “Advancing cancer research: from basic knowledge to application”; NORTE-01-0145-FEDER-000029; “Projetos Estruturados de I&D&I”, funded by Norte 2020 – Programa Operacional Regional do Norte; IPATIMUP integrates the i3S Research Unit, which is partially supported by FCT. This work is funded by FEDER funds through the Operational Programme for Competitiveness Factors – COMPETE and National Funds through the FCT, under the projects “PEst-C/SAU/LA0003/2013”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

Fundação para a Ciência e Tecnologia: SFRH/BPD/87537/2012 and SFRH/BD/87887/2012.

National Counsel of Technological and Scientific Development, Brazil. NORTE-01-0145-FEDER-000029.

Competing Interests

Paula Soares is an Academic Editor for PeerJ.

Author Contributions

- Virginia Cappagli performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables.
- Catarina Soares Potes conceived and designed the experiments, performed the experiments, analyzed the data, wrote the paper, prepared figures and/or tables.
- Luciana Bueno Ferreira performed the experiments, analyzed the data, prepared figures and/or tables.
- Catarina Tavares analyzed the data, prepared figures and/or tables.
- Catarina Eloy analyzed the data.
- Rossella Elisei reviewed drafts of the paper.
- Manuel Sobrinho-Simões reviewed drafts of the paper.
- Peter J. Wookey contributed reagents/materials/analysis tools, reviewed drafts of the paper.
- Paula Soares conceived and designed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper, reviewed drafts of the paper.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The Comissão de Ética para a Saúde (CES) do Centro Hospitalar de São João (CHSJ)/ Faculdade de Medicina da Universidade do Porto (FMUP) granted ethical approval for the study (CES 284/13).

Data Availability

The following information was supplied regarding data availability:

The raw data has been supplied as [Supplemental Dataset Files](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.3778#supplemental-information>.

REFERENCES

- Becskei C, Riediger T, Zund D, Wookey P, Lutz TA. 2004.** Immunohistochemical mapping of calcitonin receptors in the adult rat brain. *Brain Research* **1030**:221–233
DOI [10.1016/j.brainres.2004.10.012](https://doi.org/10.1016/j.brainres.2004.10.012).
- Body JJ, Glibert F, Nejai S, Fernandez G, Van Langendonck A, Borkowski A. 1990.** Calcitonin receptors on circulating normal human lymphocytes. *Journal of Clinical Endocrinology & Metabolism* **71**:675–681 DOI [10.1210/jcem-71-3-675](https://doi.org/10.1210/jcem-71-3-675).
- Bononi A, Pinton P. 2015.** Study of PTEN subcellular localization. *Methods* **77–78**:92–103
DOI [10.1016/j.ymeth.2014.10.002](https://doi.org/10.1016/j.ymeth.2014.10.002).
- Briese J, Cheng S, Ezzat S, Liu W, Winer D, Wagener C, Bamberger AM, Asa SL. 2010.** Osteopontin (OPN) expression in thyroid carcinoma. *Anticancer Research* **30**:1681–1688.
- Cafforio P, De Matteo M, Brunetti AE, Dammacco F, Silvestris F. 2009.** Functional expression of the calcitonin receptor by human T and B cells. *Human Immunology* **70**:678–685
DOI [10.1016/j.humimm.2009.05.005](https://doi.org/10.1016/j.humimm.2009.05.005).

- Chakraborty M, Chatterjee D, Kellokumpu S, Rasmussen H, Baron R. 1991.** Cell cycle-dependent coupling of the calcitonin receptor to different G proteins. *Science* **251**:1078–1082 DOI [10.1126/science.1847755](https://doi.org/10.1126/science.1847755).
- Chausmer A, Stuart C, Stevens M. 1980.** Identification of testicular cell plasma membrane receptors for calcitonin. *Journal of Laboratory and Clinical Medicine* **96**:933–938.
- Chigurupati S, Kulkarni T, Thomas S, Shah G. 2005.** Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. *Cancer Research* **65**:8519–8529 DOI [10.1158/0008-5472.CAN-05-0848](https://doi.org/10.1158/0008-5472.CAN-05-0848).
- Chung JH, Eng C. 2005.** Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. *Cancer Research* **65**:8096–8100 DOI [10.1158/0008-5472.CAN-05-1888](https://doi.org/10.1158/0008-5472.CAN-05-1888).
- Conner AC, Hay DL, Howitt SG, Kilk K, Langel U, Wheatley M, Smith DM, Poyner DR. 2002.** Interaction of calcitonin-gene-related peptide with its receptors. *Biochemical Society Transactions* **30**:451–455 DOI [10.1042/bst0300451](https://doi.org/10.1042/bst0300451).
- Davey RA, Findlay DM. 2013.** Calcitonin: physiology or fantasy? *Journal of Bone and Mineral Research* **28**:973–979 DOI [10.1002/jbmr.1869](https://doi.org/10.1002/jbmr.1869).
- deBustros A, Baylin SB, Levine MA, Nelkin BD. 1986.** Cyclic AMP and phorbol esters separately induce growth inhibition, calcitonin secretion, and calcitonin gene transcription in cultured human medullary thyroid carcinoma. *Journal of Biological Chemistry* **261**:8036–8041.
- Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR. 2013.** 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. *European Thyroid Journal* **1**:216–231 DOI [10.1159/000346174](https://doi.org/10.1159/000346174).
- Ferreira LB, Eloy C, Pestana A, Lyra J, Moura M, Prazeres H, Tavares C, Sobrinho-Simoes M, Gimba E, Soares P. 2016.** Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma. *European Journal of Endocrinology* **174**:551–561 DOI [10.1530/EJE-15-0577](https://doi.org/10.1530/EJE-15-0577).
- Findlay DM. 2006.** Regulation of cell growth mediated by the calcitonin receptor. *Cellular and Molecular Biology* **52**:3–8.
- Findlay DM, deLuise M, Michelangeli VP, Ellison M, Martin TJ. 1980.** Properties of a calcitonin receptor and adenylate cyclase in BEN cells, a human cancer cell line. *Cancer Research* **40**:1311–1317.
- Findlay DM, Michelangeli VP, Moseley JM, Martin TJ. 1981.** Calcitonin binding and degradation by two cultured human breast cancer cell lines (MCF 7 and T 47D). *Biochemical Journal* **196**:513–520 DOI [10.1042/bj1960513](https://doi.org/10.1042/bj1960513).
- Findlay DM, Michelangeli VP, Robinson PJ. 1989.** Protein kinase-C-induced down-regulation of calcitonin receptors and calcitonin-activated adenylate cyclase in T47D and BEN cells. *Endocrinology* **125**:2656–2663 DOI [10.1210/endo-125-5-2656](https://doi.org/10.1210/endo-125-5-2656).
- Fouchereau-Peron M, Moukhtar MS, Benson AA, Milhaud G. 1981.** Characterization of specific receptors for calcitonin in porcine lung. *Proceedings of the National Academy of Sciences of the United States of America* **78**:3973–3975 DOI [10.1073/pnas.78.6.3973](https://doi.org/10.1073/pnas.78.6.3973).
- Frendo JL, Delage-Mourroux R, Cohen R, Pichaud F, Pidoux E, Guliana JM, Jullienne A. 1998a.** Calcitonin receptor mRNA expression in TT cells: effect of dexamethasone. *Molecular and Cellular Endocrinology* **139**:37–43 DOI [10.1016/s0303-7207\(98\)00075-6](https://doi.org/10.1016/s0303-7207(98)00075-6).
- Frendo JL, Delage-Mourroux R, Cohen R, Pichaud F, Pidoux E, Guliana JM, Jullienne A. 1998b.** Calcitonin receptor mRNA is expressed in human medullary thyroid carcinoma. *Thyroid* **8**:141–147 DOI [10.1089/thy.1998.8.141](https://doi.org/10.1089/thy.1998.8.141).

- Frendo JL, Pichaud F, Mourroux RD, Bouizar Z, Segond N, Moukhtar MS, Jullienne A. 1994. An isoform of the human calcitonin receptor is expressed in TT cells and in medullary carcinoma of the thyroid. *FEBS Letters* 342:214–216 DOI 10.1016/0014-5793(94)80503-2.
- Gattei V, Bernabei PA, Pinto A, Bezzini R, Ringressi A, Formigli L, Tanini A, Attadia V, Brandi ML. 1992. Phorbol ester induced osteoclast-like differentiation of a novel human leukemic cell line (FLG 29.1). *Journal of Cell Biology* 116:437–447 DOI 10.1083/jcb.116.2.437.
- Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ, Findlay DM. 1997. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. *International Journal of Cancer* 73:812–815 DOI 10.1002/(sici)1097-0215(19971210)73:6<812::aid-ijc7>3.3.co;2-q.
- Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT, Walsh NC, Chia LY, Quinn JM, Martin TJ, Sims NA. 2010. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. *Bone* 46:1486–1497 DOI 10.1016/j.bone.2010.02.018.
- Gorn AH, Lin HY, Yamin M, Auron PE, Flannery MR, Tapp DR, Manning CA, Lodish HF, Krane SM, Goldring SR. 1992. Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line. *Journal of Clinical Investigation* 90:1726–1735 DOI 10.1172/JCI116046.
- Gorn AH, Rudolph SM, Flannery MR, Morton CC, Weremowicz S, Wang TZ, Krane SM, Goldring SR. 1995. Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction. *Journal of Clinical Investigation* 95:2680–2691 DOI 10.1172/JCI117970.
- Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K. 2006. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. *International Journal of Oncology* 28:807–814 DOI 10.3892/ijo.28.4.807.
- Jagger C, Chambers T, Pondel M. 2000. Transgenic mice reveal novel sites of calcitonin receptor gene expression during development. *Biochemical and Biophysical Research Communications* 274:124–129 DOI 10.1006/bbrc.2000.3093.
- Johansson E, Andersson L, Ornskold J, Carlsson T, Ingesson-Carlsson C, Liang S, Dahlberg J, Jansson S, Parrillo L, Zoppoli P, Barila GO, Altschuler DL, Padula D, Lickert H, Fagman H, Nilsson M. 2015. Revising the embryonic origin of thyroid C cells in mice and humans. *Development* 142:3519–3528 DOI 10.1242/dev.126581.
- Kakudo K, Itoh J, Takekoshi S, Watanabe K. 1989. Effects of synthetic salmon calcitonin on C cells of the thyroid. *Pathology International* 39:545–550 DOI 10.1111/j.1440-1827.1989.tb02482.x.
- Keller J, Catala-Lehnen P, Huebner AK, Jeschke A, Heckt T, Lueth A, Krause M, Koehne T, Albers J, Schulze J, Schilling S, Haberland M, Denninger H, Neven M, Hermans-Borgmeyer I, Streichert T, Breer S, Barvencik F, Levkau B, Rathkolb B, Wolf E, Calzada-Wack J, Neff F, Gailus-Durner V, Fuchs H, de Angelis MH, Klutmann S, Tsourdi E, Hofbauer LC, Kleuser B, Chun J, Schinke T, Amling M. 2014. Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. *Nature Communications* 5:5215 DOI 10.1038/ncomms6215.
- Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. 2009. Medullary thyroid cancer: management guidelines of the American Thyroid Association. *Thyroid* 19:565–612 DOI 10.1089/thy.2008.0403.
- Koperek O, Scheuba C, Cherenko M, Neuhold N, De Micco C, Schmid KW, Niederle B, Kaserer K. 2008. Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential. *Histopathology* 52:623–630 DOI 10.1111/j.1365-2559.2008.03002.x.

- Kuestner RE, Elrod RD, Grant FJ, Hagen FS, Kuijper JL, Matthewes SL, O'Hara PJ, Sheppard PO, Stroop SD, Thompson DL. 1994. Cloning and characterization of an abundant subtype of the human calcitonin receptor. *Molecular Pharmacology* 46:246–255.
- Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, Kolakowski LF Jr, Yamin M, Lodish HF, Goldring SR. 1991. Expression cloning and characterization of a porcine renal calcitonin receptor. *Transactions of the Association of American Physicians* 104:265–272.
- Lyra J, Vinagre J, Batista R, Pinto V, Prazeres H, Rodrigues F, Eloy C, Sobrinho-Simoes M, Soares P. 2014. mTOR activation in medullary thyroid carcinoma with RAS mutation. *European Journal of Endocrinology* 171:633–640 DOI 10.1530/EJE-14-0389.
- Marx SJ, Aurbach GD, Gavin JR 3rd, Buell DW. 1974. Calcitonin receptors on cultured human lymphocytes. *Journal of Biological Chemistry* 249:6812–6816.
- Morimoto S, Birge SJ, Fausto A, Avioli LV. 1984. Inhibition of calcitonin secretion by exogenous calcitonin in the rat. *Endocrinology* 115:60–64 DOI 10.1210/endo-115-1-60.
- Muff R, Born W, Lutz TA, Fischer JA. 2004. Biological importance of the peptides of the calcitonin family as revealed by disruption and transfer of corresponding genes. *Peptides* 25:2027–2038 DOI 10.1016/j.peptides.2004.08.007.
- Nakamura M, Han B, Nishishita T, Bai Y, Kakudo K. 2007. Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers. *Journal of Molecular Endocrinology* 39:375–384 DOI 10.1677/JME-07-0036.
- Ng KW, Livesey SA, Larkins RG, Martin TJ. 1983. Calcitonin effects on growth and on selective activation of type II isoenzyme of cyclic adenosine 3':5'-monophosphate-dependent protein kinase in T 47D human breast cancer cells. *Cancer Research* 43:794–800.
- Nicholson GC, Horton MA, Sexton PM, D'Santos CS, Moseley JM, Kemp BE, Pringle JA, Martin TJ. 1987. Calcitonin receptors of human osteoclastoma. *Hormone and Metabolic Research* 19:585–589 DOI 10.1055/s-2007-1011887.
- Orme AL, Pento JT. 1976. Evidence of calcitonin-induced inhibition of calcitonin secretion in porcine thyroid slices. *Experimental Biology and Medicine* 151:110–112 DOI 10.3181/00379727-151-39154.
- Pacini F, Castagna MG, Cipri C, Schlumberger M. 2010. Medullary thyroid carcinoma. *Clinical Oncology (Royal College of Radiologists)* 22:475–485 DOI 10.1016/j.clon.2010.05.002.
- Pondel M. 2000. Calcitonin and calcitonin receptors: bone and beyond. *International Journal of Experimental Pathology* 81:405–422 DOI 10.1046/j.1365-2613.2000.00176.x.
- Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. 2002. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, calcitonin receptors. *Pharmacological Reviews* 54:233–246 DOI 10.1124/pr.54.2.233.
- Rowley DR. 1998. What might a stromal response mean to prostate cancer progression? *Cancer and Metastasis Reviews* 17:411–419.
- Scheuba C, Kaserer K, Kaczirek K, Asari R, Niederle B. 2006. Desmoplastic stromal reaction in medullary thyroid cancer: an intraoperative “marker” for lymph node metastases. *World Journal of Surgery* 30:853–859 DOI 10.1007/s00268-005-0391-4.
- Sexton PM, McKenzie JS, Mendelsohn FAO. 1988. Evidence for a new subclass of calcitonin/calcitonin gene-related peptide binding sites in rat brain. *Neurochemistry International* 12:323–335 DOI 10.1016/0197-0186(88)90171-4.
- Shah GV, Muralidharan A, Gokulgandhi M, Soan K, Thomas S. 2009. Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin–calcitonin

- receptor axis in prostate cancer. *Journal of Biological Chemistry* **284**:1018–1030
DOI [10.1074/jbc.M807823200](https://doi.org/10.1074/jbc.M807823200).
- Silvestris F, Cafforio P, De Matteo M, Quatraro C, Dammacco F. 2008.** Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. *Leukemia Research* **32**:611–623 DOI [10.1016/j.leukres.2007.07.009](https://doi.org/10.1016/j.leukres.2007.07.009).
- Tamburrino A, Molinolo AA, Salerno P, Chernock RD, Raffeld M, Xi L, Gutkind JS, Moley JF, Wells SA Jr, Santoro M. 2012.** Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. *Clinical Cancer Research* **18**:3532–3540
DOI [10.1158/1078-0432.CCR-11-2700](https://doi.org/10.1158/1078-0432.CCR-11-2700).
- Thakkar A, Bijnsdorp IV, Geldof AA, Shah GV. 2013.** Profiling of the calcitonin–calcitonin receptor axis in primary prostate cancer: clinical implications and molecular correlates. *Oncology Reports* **30**:1265–1274 DOI [10.3892/or.2013.2583](https://doi.org/10.3892/or.2013.2583).
- Thomas S, Chigurupati S, Anbalagan M, Shah G. 2006.** Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor. *Molecular Endocrinology* **20**:1894–1911 DOI [10.1210/me.2005-0284](https://doi.org/10.1210/me.2005-0284).
- Thomas S, Muralidharan A, Shah GV. 2007.** Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells. *International Journal of Oncology* **31**:1425–1437.
- Tikellis C, Xuereb L, Casley D, Brasier G, Cooper ME, Wookey PJ. 2003.** Calcitonin receptor isoforms expressed in the developing rat kidney. *Kidney International* **63**:416–426
DOI [10.1046/j.1523-1755.2003.00754.x](https://doi.org/10.1046/j.1523-1755.2003.00754.x).
- Tlsty TD, Coussens LM. 2006.** Tumor stroma and regulation of cancer development. *Annual Review of Pathology: Mechanisms of Disease* **1**:119–150
DOI [10.1146/annurev.pathol.1.110304.100224](https://doi.org/10.1146/annurev.pathol.1.110304.100224).
- Tolcos M, Tikellis C, Rees S, Cooper M, Wookey P. 2003.** Ontogeny of calcitonin receptor mRNA and protein in the developing central nervous system of the rat. *Journal of Comparative Neurology* **456**:29–38 DOI [10.1002/cne.10478](https://doi.org/10.1002/cne.10478).
- Turner AG, Tjahyono F, Chiu WS, Skinner J, Sawyer R, Moore AJ, Morris HA, Findlay DM, Zajac JD, Davey RA. 2011.** The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption. *Bone* **48**:354–361 DOI [10.1016/j.bone.2010.09.013](https://doi.org/10.1016/j.bone.2010.09.013).
- Wang X, Nakamura M, Mori I, Takeda K, Nakamura Y, Utsunomiya H, Yoshimura G, Sakurai T, Kakudo K. 2004.** Calcitonin receptor gene and breast cancer: quantitative analysis with laser capture microdissection. *Breast Cancer Research and Treatment* **83**:109–117
DOI [10.1023/B:BREA.0000010703.59483.c0](https://doi.org/10.1023/B:BREA.0000010703.59483.c0).
- Wimalawansa SJ. 1997.** Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. *Critical Reviews in Neurobiology* **11**:167–239
DOI [10.1615/critrevneurobiol.v11.i2-3.40](https://doi.org/10.1615/critrevneurobiol.v11.i2-3.40).
- Wookey PJ, McLean CA, Hwang P, Furness SG, Nguyen S, Kourakis A, Hare DL, Rosenfeld JV. 2012a.** The expression of calcitonin receptor detected in malignant cells of the brain tumour glioblastoma multiforme and functional properties in the cell line A172. *Histopathology* **60**:895–910 DOI [10.1111/j.1365-2559.2011.04146.x](https://doi.org/10.1111/j.1365-2559.2011.04146.x).
- Wookey PJ, Turner K, Furness JB. 2012b.** Transient expression of the calcitonin receptor by enteric neurons of the embryonic and early post-natal mouse. *Cell and Tissue Research* **347**:311–317 DOI [10.1007/s00441-011-1303-6](https://doi.org/10.1007/s00441-011-1303-6).

- Wookey PJ, Zulli A, Buxton BF, Hare DL. 2008.** Calcitonin receptor immunoreactivity associated with specific cell types in diseased radial and internal mammary arteries. *Histopathology* 52:605–612 DOI [10.1111/j.1365-2559.2008.02979.x](https://doi.org/10.1111/j.1365-2559.2008.02979.x).
- Wookey PJ, Zulli A, Hare DL. 2009.** The elevated expression of calcitonin receptor by cells recruited into the endothelial layer and neo-intima of atherosclerotic plaque. *Histochemistry and Cell Biology* 132:181–189 DOI [10.1007/s00418-009-0600-6](https://doi.org/10.1007/s00418-009-0600-6).
- Wookey P, Zulli A, Lo C, Hare D, Schwarzer A, Darby I, Leung A. 2010.** Calcitonin receptor (CTR) expression in embryonic, foetal and adult tissues: developmental and pathophysiological implications. In: Hay D, Dickerson I, eds. *The Calcitonin Gene-Related Peptide Family; Form, Function and Future Perspectives*. Netherlands: Springer, 199–233.